NVAX Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -91.76% compared to Novavax's net margin of 32.59%. Novavax's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Novavax has a consensus price target of $16.43, signalling upside risk potential of 115.88%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 20.64%. Given that Novavax has higher upside potential than Eli Lilly and, analysts believe Novavax is more attractive than Eli Lilly and.

Novavax has a beta of 2.916, which suggesting that the stock is 191.569% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Novavax pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax quarterly revenues are $88.3M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Novavax's net income of -$81M is lower than Eli Lilly and's net income of $4.4B. Notably, Novavax's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 71.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.75x versus 16.81x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -91.76% compared to Novavax's net margin of 23.96%. Novavax's return on equity of -- beat Merck &'s return on equity of 40.25%.

Novavax has a consensus price target of $16.43, signalling upside risk potential of 115.88%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 20.36%. Given that Novavax has higher upside potential than Merck &, analysts believe Novavax is more attractive than Merck &.

Novavax has a beta of 2.916, which suggesting that the stock is 191.569% more volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.39% to investors and pays a quarterly dividend of $0.81 per share. Novavax pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax quarterly revenues are $88.3M, which are smaller than Merck & quarterly revenues of $15.6B. Novavax's net income of -$81M is lower than Merck &'s net income of $3.7B. Notably, Novavax's price-to-earnings ratio is -- while Merck &'s PE ratio is 13.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.75x versus 3.69x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -91.76% compared to Novavax's net margin of -117.16%. Novavax's return on equity of -- beat Moderna's return on equity of -29.09%.

Novavax has a consensus price target of $16.43, signalling upside risk potential of 115.88%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 63.63%. Given that Novavax has higher upside potential than Moderna, analysts believe Novavax is more attractive than Moderna.

Novavax has a beta of 2.916, which suggesting that the stock is 191.569% more volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Novavax quarterly revenues are $88.3M, which are smaller than Moderna quarterly revenues of $956M. Novavax's net income of -$81M is higher than Moderna's net income of -$1.1B. Notably, Novavax's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.75x versus 3.96x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -91.76% compared to Novavax's net margin of 2.31%. Novavax's return on equity of -- beat Pfizer's return on equity of 8.91%.

Novavax has a consensus price target of $16.43, signalling upside risk potential of 115.88%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 18.92%. Given that Novavax has higher upside potential than Pfizer, analysts believe Novavax is more attractive than Pfizer.

Novavax has a beta of 2.916, which suggesting that the stock is 191.569% more volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.43% to investors and pays a quarterly dividend of $0.43 per share. Novavax pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Novavax quarterly revenues are $88.3M, which are smaller than Pfizer quarterly revenues of $17.8B. Novavax's net income of -$81M is lower than Pfizer's net income of $410M. Notably, Novavax's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.75x versus 2.35x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.